Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - VYNE Therapeutics Inc. | mnlo-ex321_7.htm |
| EX-31.2 - EX-31.2 - VYNE Therapeutics Inc. | mnlo-ex312_6.htm |
| EX-31.1 - EX-31.1 - VYNE Therapeutics Inc. | mnlo-ex311_8.htm |
| EX-4.4 - EX-4.4 - VYNE Therapeutics Inc. | mnlo-ex44_366.htm |
| 10-K - 10-K - VYNE Therapeutics Inc. | mnlo-10k_20191231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
(1) |
Registration Statement (Form S-3 No. 333-229482) of Menlo Therapeutics Inc.; and |
|
(2) |
Registration Statements (Form S-8 Nos. 333-222758 and 333-229975) pertaining to the 2011 Stock Incentive Plan, as amended, 2018 Omnibus Incentive Plan and 2018 Employee Stock Purchase Plan of Menlo Therapeutics Inc.; and |
(3) Registration Statement (Form S-4 No. 333-235351) of Menlo Therapeutics Inc.;
of our report dated March 3, 2020, with respect to the financial statements of Menlo Therapeutics Inc. included in this Annual Report (Form 10-K) as of December 31, 2019 and 2018 and for the three years then ended.
/s/ Mayer Hoffman McCann P.C.
San Diego, California
March 3, 2020